title: Management of bladder, prostatic and pelvic floor disorders with botulinum neurotoxin.
abstract: Since its introduction in the late 1970s for the treatment of strabismus and blepharospasm, botulinum toxin (BoNT) has been increasingly used in the interventional treatment of several other disorders characterized by excessive or inappropriate muscle contractions. The use of this pluripotential agent has extended to a plethora of conditions including: focal dystonia; spasticity; inappropriate contraction in most sphincters of the body such as those associated with spasmodic dysphonia, esophageal achalasia, chronic anal fissure, and vaginismus; eye movement disorders; other hyperkinetic disorders including tics and tremors; autonomic disorders such as hyperhidrosis; genitourinary disorders such as overactive and neurogenic bladder, non-bacterial prostatitis and benign prostatic hyperplasia; and aesthetically undesirable hyperfunctional facial lines. In addition, BoNT is being investigated for the control of the pain, and for the management of tension or migraine headaches and myofascial pain syndrome. BoNT injections have several advantages over drugs and surgical therapies in the management of intractable or chronic disease. Systemic pharmacologic effects are rare; permanent destruction of tissue does not occur. Graded degrees of relaxation may be achieved by varying the dose injected; most adverse effects are transient. Finally, patient acceptance is high. In this paper, clinical experience over the last years with BoNT in urological impaired patients will be illustrated. Moreover, this paper presents current data on the use of BoNT to treat pelvic floor disorders.
authors.affiliation: Department of Surgery, Catholic School of Medicine, University Hospital Agostino Gemelli, Rome, Italy.
authors.forename: G
authors.initials: G
authors.lastname: Maria
authors.forename: F
authors.initials: F
authors.lastname: Cadeddu
authors.forename: D
authors.initials: D
authors.lastname: Brisinda
authors.forename: F
authors.initials: F
authors.lastname: Brandara
authors.forename: G
authors.initials: G
authors.lastname: Brisinda
mesh_terms: D019274:Botulinum Toxins, Type A / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use*; D002648:Child; D003248:Constipation / Q000188:drug therapy; D005401:Fissure in Ano / Q000188:drug therapy; D006801:Humans; D007267:Injections; D008297:Male; D017773:Pelvic Floor; D011469:Prostatic Diseases / Q000188:drug therapy; D011941:Receptors, Adrenergic / Q000187:drug effects; D011950:Receptors, Cholinergic / Q000187:drug effects; D001745:Urinary Bladder Diseases / Q000188:drug therapy; D014551:Urinary Tract / Q000187:drug effects; D014553:Urinary Tract Physiological Phenomena / Q000187:drug effects; D014570:Urologic Diseases / Q000188:drug therapy*
chemical_list: D011941:Receptors, Adrenergic; D011950:Receptors, Cholinergic; D019274:Botulinum Toxins, Type A